BPC-157

BPC-157 (Body Protective Compound-157) is a synthetic 15-amino-acid pentadecapeptide derived from a partial sequence of body protection compound (BPC) found in human gastric juice. It is one of the most-researched peptides in the tissue repair and gut healing space, with an extensive preclinical research base developed predominantly by Predrag Sikirić's group at the University of Zagreb. Important regulatory update: BPC-157 was removed from the FDA's Category 2 bulk drug substances list on April 22, 2026 because the nomination had been withdrawn by the nominators, and at its July 23–24, 2026 meeting the Pharmacy Compounding Advisory Committee voted 8–6–1 to recommend it for the 503A compounding bulks list — an advisory recommendation only, which FDA scientific staff opposed and the agency has not finalized.

What is BPC-157 and how does the gastric-juice-derived mechanism work?

BPC-157 is a synthetic 15-amino-acid pentadecapeptide derived from a partial sequence of a body protection compound originally identified in human gastric juice, proposed to act through multiple mechanisms: VEGF and growth hormone receptor upregulation, nitric oxide pathway modulation, GHRH receptor effects, and angiogenesis stimulation. The compound's tissue-protective and tissue-repair effects appear to be multi-pathway rather than single-receptor, with the Sikirić group's extensive research characterizing effects across virtually every organ system.

Evidence level: preclinical extensive (multiple organ systems, tissue repair, gut healing); limited human clinical research; FDA PCAC recommended it 8–6–1 for the 503A bulks list (July 2026, advisory, not finalized)

What does the research show for BPC-157?

Preclinical studies have demonstrated effects on tendon and ligament healing, gut inflammation reduction, ulcer healing, vascular protection, and broad tissue-repair mechanisms across rodent and other animal models. The Sikirić group has produced over 200 publications characterizing BPC-157 effects — the BPC-157 healing-mechanism and safety science review traces this literature back to Sikirić's foundational gastric-pentadecapeptide work. The preclinical base is genuinely large, but the human record is not: no randomized controlled trial of BPC-157 has been published, and the clinical literature is a handful of small, uncontrolled pilot reports totalling roughly 31 subjects. A 2025 orthopaedic systematic review screened 544 records and found only a single clinical study of BPC-157 among them — an uncontrolled retrospective case series of intra-articular BPC-157 for knee pain (about 16 patients, 12 of them on BPC-157 alone), with no control group. At its July 2026 meeting the Pharmacy Compounding Advisory Committee voted 8–6–1 to recommend BPC-157 for the 503A compounding bulks list — advisory only, not finalized.

Sources: A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC, Sikirić P. et al., J Physiol Paris, 1993; Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review, Vasireddi N. et al., HSS J, 2025; Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain, Lee E., Padgett B., Alternative Therapies in Health and Medicine, 2021 · Evidence level: preclinical extensive (200+ Sikirić publications across organ systems); human clinical limited; PCAC recommended 8–6–1 (July 2026, advisory)

How does BPC-157 compare to other tissue-repair peptides?

A marketed analog, "pentadeca arginate" (PDA), is BPC-157's identical 15-amino-acid sequence supplied as an arginine salt rather than the acetate. It is a formulation variant of the same peptide, not a distinct molecule, and it has no published research of its own — see Pentadeca Arginate.

BPC-157 has the largest preclinical research base of any tissue-repair peptide in the Peptigrity catalog, and the most advanced FDA regulatory pathway among non-approved compounds — but the underlying human clinical evidence base remains less developed than the preclinical research suggests.

What are the documented side effects of BPC-157?

Side effects in available preclinical safety data and community-reported research use are generally mild — injection-site reactions are the most common report. The Sikirić group has emphasized a favorable preclinical safety profile across animal studies. Long-term safety in humans at sustained research-use dosing is not characterized at Western RCT standards. Theoretical concerns about angiogenesis effects (relevant for cancer biology) have been raised but not clinically substantiated.

Evidence level: preclinical safety extensive; human long-term unestablished; theoretical angiogenesis concerns unaddressed at human standards

What is the regulatory status of BPC-157?

BPC-157 is not approved for any medical indication anywhere in the world as of August 2026. On April 22, 2026 the FDA removed BPC-157 from its Category 2 bulk drug substances list because the nomination had been withdrawn by the nominators — the agency's own framing. Removal did not place BPC-157 on the 503A bulks list or into Category 1, and does not by itself authorize compounding. At its July 23–24, 2026 meeting the FDA's Pharmacy Compounding Advisory Committee voted 8–6–1 to recommend BPC-157 for the 503A compounding bulks list. This is an advisory recommendation only: FDA scientific staff recommended against it, the agency has not adopted it, and compounding remains unlawful under 503A until the FDA completes formal rulemaking (not expected before 2027). Current status in FDA peptide regulation 2025–2026 timeline.

Sources: FDA Announces Removal of 12 Peptides from Category 2 (nominations withdrawn by the nominators) and Schedules PCAC Meetings, Orrick (legal analysis of the FDA notice), via Orrick Insights; PCAC July 23–24 2026 meeting outcome, FDA PCAC, via Buchanan Ingersoll / Clinical Peptide / NCPA / AJMC

Why does BPC-157 vendor verification matter?

BPC-157 is among the highest-volume peptides in research-grade markets, with substantial quality variance and occasional mislabeling — and the 15-amino-acid length makes synthesis quality control more important than for shorter peptides. Independent HPLC purity testing and mass spectrometry identity confirmation are essential. Some vendors sell BPC-157 acetate versus BPC-157 free base without clear labeling — the PCAC review specifically addresses both forms. Guidance in how-to-test-peptides hub.

How does Peptigrity verify BPC-157 vendors?

Peptigrity collects independent third-party Certificates of Analysis for BPC-157 from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. The lab test table above this section shows the cross-shop dataset. Methodology in how we calculate trust scores.

Frequently asked questions

What does BPC-157 do?

BPC-157 is researched extensively for tissue repair, gut healing, tendon and ligament recovery, ulcer healing, and broad tissue-protective effects across multiple organ systems. The preclinical base is substantial (200+ publications), but no randomized controlled trial of BPC-157 has been published — the human literature is a handful of small, uncontrolled pilot reports. At its July 2026 meeting the Pharmacy Compounding Advisory Committee voted 8–6–1 to recommend BPC-157 for the 503A compounding bulks list — advisory only, not finalized.

Is BPC-157 legal to purchase?

BPC-157 is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption. The April 22, 2026 Category 2 removal reflects a withdrawn nomination, and the July 2026 PCAC vote was advisory only — neither authorizes compounding, and compounding stays unlawful under 503A pending formal rulemaking. Country breakdown in peptide legal status guide.

When will the FDA decide on BPC-157?

It already met — and the FDA has not decided. At its July 23–24, 2026 meeting the Pharmacy Compounding Advisory Committee voted 8–6–1 to recommend BPC-157 for the 503A bulks list. That recommendation is advisory: FDA scientific staff recommended against it, the agency has not adopted it, and formal rulemaking is projected for 2027 or later, so compounding remains unlawful under 503A in the meantime. Track developments in FDA peptide regulation 2025–2026 timeline.

Source: PCAC July 23–24 2026 meeting outcome, FDA PCAC, via Buchanan Ingersoll / Clinical Peptide / NCPA / AJMC

Does BPC-157 cause cancer?

The theoretical angiogenesis-related concern (BPC-157's vascular effects could theoretically support tumor angiogenesis) has been raised in mechanism discussions but has not been clinically substantiated in available data. Long-term human surveillance has not been conducted at scale. Anyone with active cancer or cancer history should consult a licensed physician before considering BPC-157.

How can I verify a BPC-157 vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation. Some vendors don't clearly distinguish BPC-157 acetate versus BPC-157 free base — verify which form is being sold. COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend a BPC-157 dose?

No. BPC-157 is not approved for human consumption and Peptigrity is an independent review platform, not a medical authority. Research-use dosing in community protocols varies widely by indication. Anyone considering use should consult a licensed physician — particularly given the July 2026 FDA review which may change the regulatory landscape.

Does BPC-157 show up on a drug test?

Yes. BPC-157 is prohibited by WADA at all times (in and out of competition) under S0 (non-approved substances) — the class for substances with no current regulatory approval for human use — so athletes in tested sport are subject to it as of August 2026. Detection methods for BPC-157 are evolving. For drug-testing context, see do peptides show up on drug tests.

Source: WADA Prohibited List (current year)

This section is for educational and informational purposes only and does not constitute medical advice. BPC-157 is not approved by the FDA or any major Western regulator for human use, though it was removed from Category 2 of the FDA 503A bulk substances list in April 2026 and is scheduled for PCAC review on July 23, 2026 for the proposed use in ulcerative colitis. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.